Trial Profile
A Phase I, Multi-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics/Pharmacodynamics of JMT103 in Patients With Bone Metastases From Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Narlumosbart (Primary)
- Indications Advanced breast cancer; Bone metastases; Colorectal cancer; Gastric cancer; Lung cancer; Rectal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Shanghai Jinmante Biotechnology
- 31 May 2020 Results (n=56; as of Jan 2020) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jan 2019 According to a CSPC Pharmaceutical Group, the company has received the IND application approval in March 2017 from the NMPA (National Medical Products Administration of the PRC ( The People's Republic of China)) to initiate this study in patients with bone metastases from solid tumors. As of now, this study is almost completed.
- 15 Jun 2018 New trial record